Simplify Asset Management Inc. Lowers Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Simplify Asset Management Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 52.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,167 shares of the biopharmaceutical company's stock after selling 50,035 shares during the period. Gilead Sciences makes up approximately 0.2% of Simplify Asset Management Inc.'s holdings, making the stock its 28th largest holding. Simplify Asset Management Inc.'s holdings in Gilead Sciences were worth $4,264,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences in the fourth quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the 4th quarter valued at $29,000. Crews Bank & Trust bought a new position in Gilead Sciences in the 4th quarter worth $31,000. Finally, Stephens Consulting LLC lifted its position in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares during the period. Institutional investors own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by company insiders.

Remove Ads

Analyst Ratings Changes

Several equities analysts recently issued reports on GILD shares. Piper Sandler boosted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Oppenheimer increased their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 4th. The Goldman Sachs Group lifted their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Stock Performance

GILD traded up $1.89 during midday trading on Thursday, hitting $111.16. 6,382,732 shares of the company traded hands, compared to its average volume of 6,806,689. The company's 50-day moving average is $105.08 and its 200 day moving average is $94.58. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $138.43 billion, a PE ratio of 300.43, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.